Jacobs Levy Equity Management, Inc Karyopharm Therapeutics Inc. Transaction History

Jacobs Levy Equity Management, Inc

$24.7 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.68 - $1.31 $1.41 Million - $2.71 Million	-2,069,071 Reduced 87.91%	284,457 $244,000
Q3 2023 Nov 16, 2023	BUY	$1.14 - $1.81 $1.91 Million - $3.03 Million	1,676,673 Added 247.72%	2,353,528 $3.15 Million
Q2 2023 Aug 14, 2023	SELL	$1.79 - $4.59 $712,812 - $1.83 Million	-398,219 Reduced 37.04%	676,855 $1.21 Million
Q1 2023 May 15, 2023	SELL	$2.84 - $3.92 $3.34 Million - $4.6 Million	-1,174,325 Reduced 52.21%	1,075,074 $4.18 Million
Q4 2022 Feb 14, 2023	BUY	$2.48 - $5.93 $1.65 Million - $3.95 Million	666,875 Added 42.14%	2,249,399 $7.65 Million
Q3 2022 Nov 15, 2022	BUY	$4.08 - $5.82 $226,374 - $322,916	55,484 Added 3.63%	1,582,524 $8.64 Million
Q2 2022 Aug 15, 2022	BUY	$4.15 - $8.37 $3.58 Million - $7.23 Million	863,528 Added 130.15%	1,527,040 $6.89 Million
Q1 2022 May 16, 2022	BUY	$5.91 - $14.38 $3.92 Million - $9.54 Million	663,512 New	663,512 $4.89 Million
Q3 2021 Nov 15, 2021	SELL	$4.45 - $10.63 $361,593 - $863,761	-81,257 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$8.11 - $11.11 $658,994 - $902,765	81,257 New	81,257 $839,000
Q1 2021 May 17, 2021	SELL	$9.85 - $17.69 $418,812 - $752,161	-42,519 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$14.15 - $17.19 $601,643 - $730,901	42,519 New	42,519 $658,000
Q1 2020 May 15, 2020	SELL	$14.38 - $27.72 $1.91 Million - $3.67 Million	-132,505 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$9.23 - $19.67 $551,077 - $1.17 Million	59,705 Added 82.01%	132,505 $2.54 Million
Q3 2019 Nov 14, 2019	BUY	$5.66 - $11.85 $412,048 - $862,680	72,800 New	72,800 $700,000
Q1 2019 May 14, 2019	SELL	$4.12 - $10.25 $120,716 - $300,325	-29,300 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$8.2 - $16.95 $819 - $1,695	100 Added 0.34%	29,300 $275,000
Q3 2018 Nov 14, 2018	SELL	$17.03 - $21.18 $538,148 - $669,288	-31,600 Reduced 51.97%	29,200 $497,000
Q2 2018 Aug 14, 2018	BUY	$12.0 - $19.88 $105,600 - $174,944	8,800 Added 16.92%	60,800 $1.03 Million
Q1 2018 May 15, 2018	SELL	$9.92 - $17.25 $11,904 - $20,700	-1,200 Reduced 2.26%	52,000 $698,000
Q4 2017 Feb 13, 2018	BUY	$9.15 - $11.99 $261,690 - $342,914	28,600 Added 116.26%	53,200 $511,000
Q3 2017 Nov 14, 2017	BUY	$8.15 - $11.16 $92,910 - $127,224	11,400 Added 86.36%	24,600 $270,000
Q2 2017 Nov 09, 2017	BUY	N/A	13,200	13,200 $119,000

Others Institutions Holding KPTI

# of Institutions

Shares Held

57.6M

Call Options Held

258K

Put Options Held

81.2K

Vanguard Group Inc Valley Forge, PA

7.65M
Shares

$5.21 Million
0.0% of portfolio
Eversept Partners, LP New York, NY

5.55M
Shares

$3.77 Million
0.36% of portfolio
Palo Alto Investors LP Palo Alto, CA

5.1M
Shares

$3.47 Million
0.58% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

4.32M
Shares

$2.94 Million
0.01% of portfolio
Black Rock Inc. New York, NY

4.17M
Shares

$2.84 Million
0.0% of portfolio

View Full List

About Karyopharm Therapeutics Inc.

Ticker KPTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 79,806,600
Market Cap $54.3M
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and in...

More about KPTI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Account